Avalo Therapeutics (AVTX) Competitors

Avalo Therapeutics logo
$6.72 -0.03 (-0.44%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AVTX vs. RARE, IMCR, NBTX, QURE, and NUVB

Should you buy Avalo Therapeutics stock or one of its competitors? Avalo Therapeutics's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), Immunocore (IMCR), Nanobiotix (NBTX), uniQure (QURE), and Nuvation Bio (NUVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avalo Therapeutics compare to Ultragenyx Pharmaceutical?

Avalo Therapeutics (NASDAQ:AVTX) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Avalo Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -71.78%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A -34.21% -29.84%
Ultragenyx Pharmaceutical -71.78%N/A -39.70%

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Avalo Therapeutics presently has a consensus target price of $36.82, suggesting a potential upside of 445.45%. Ultragenyx Pharmaceutical has a consensus target price of $29.79, suggesting a potential upside of 72.99%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Avalo Therapeutics is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45

Avalo Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A
Ultragenyx Pharmaceutical$673M2.61-$575M-$5.19N/A

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.34 beat Ultragenyx Pharmaceutical's score of 0.17 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Avalo Therapeutics beats Ultragenyx Pharmaceutical on 10 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Immunocore?

Avalo Therapeutics (NASDAQ:AVTX) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Avalo Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -7.48%. Immunocore's return on equity of -7.96% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Avalo TherapeuticsN/A -34.21% -29.84%
Immunocore -7.48%-7.96%-2.93%

Avalo Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 10.1% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Immunocore has higher revenue and earnings than Avalo Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A
Immunocore$400.02M3.43-$35.51M-$0.65N/A

In the previous week, Immunocore had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for Immunocore and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.34 beat Immunocore's score of -0.44 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immunocore
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Avalo Therapeutics presently has a consensus price target of $36.82, suggesting a potential upside of 445.45%. Immunocore has a consensus price target of $52.86, suggesting a potential upside of 98.49%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Avalo Therapeutics is more favorable than Immunocore.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71
Immunocore
2 Sell rating(s)
3 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

Immunocore beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Avalo Therapeutics compare to Nanobiotix?

Nanobiotix (NASDAQ:NBTX) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

38.8% of Nanobiotix shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 3.5% of Nanobiotix shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nanobiotix has higher revenue and earnings than Avalo Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$36.87M37.77-$27.11MN/AN/A
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A

In the previous week, Avalo Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for Avalo Therapeutics and 0 mentions for Nanobiotix. Avalo Therapeutics' average media sentiment score of 0.34 beat Nanobiotix's score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Nanobiotix Neutral
Avalo Therapeutics Neutral

Nanobiotix has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

Nanobiotix's return on equity of 0.00% beat Avalo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
Avalo Therapeutics N/A -34.21%-29.84%

Nanobiotix currently has a consensus target price of $46.67, suggesting a potential upside of 70.82%. Avalo Therapeutics has a consensus target price of $36.82, suggesting a potential upside of 445.45%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Nanobiotix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

Summary

Avalo Therapeutics beats Nanobiotix on 8 of the 13 factors compared between the two stocks.

How does Avalo Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, uniQure had 3 more articles in the media than Avalo Therapeutics. MarketBeat recorded 6 mentions for uniQure and 3 mentions for Avalo Therapeutics. uniQure's average media sentiment score of 0.51 beat Avalo Therapeutics' score of 0.34 indicating that uniQure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
uniQure
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

uniQure has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

78.8% of uniQure shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

uniQure presently has a consensus price target of $55.58, suggesting a potential upside of 174.76%. Avalo Therapeutics has a consensus price target of $36.82, suggesting a potential upside of 445.45%. Given Avalo Therapeutics' higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

Avalo Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.84%. Avalo Therapeutics' return on equity of -34.21% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,154.84% -96.34% -26.40%
Avalo Therapeutics N/A -34.21%-29.84%

Avalo Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$16.10M88.13-$198.97M-$3.51N/A
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A

Summary

uniQure beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Avalo Therapeutics compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Avalo Therapeutics has a net margin of 0.00% compared to Nuvation Bio's net margin of -67.38%. Avalo Therapeutics' return on equity of -34.21% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-67.38% -45.69% -18.54%
Avalo Therapeutics N/A -34.21%-29.84%

Nuvation Bio currently has a consensus target price of $13.00, suggesting a potential upside of 239.96%. Avalo Therapeutics has a consensus target price of $36.82, suggesting a potential upside of 445.45%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Avalo Therapeutics is more favorable than Nuvation Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Avalo Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Nuvation Bio had 7 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for Nuvation Bio and 3 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.34 beat Nuvation Bio's score of -0.03 indicating that Avalo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Avalo Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nuvation Bio has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Avalo Therapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$62.90M21.46-$204.63M-$0.40N/A
Avalo Therapeutics$60K6,504.75-$78.26M-$2.52N/A

Summary

Avalo Therapeutics beats Nuvation Bio on 9 of the 15 factors compared between the two stocks.

Get Avalo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVTX vs. The Competition

MetricAvalo TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$391.15M$3.97B$7.50B$11.20B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-2.6823.8132.7529.11
Price / Sales6,485.4815.588.155.36
Price / CashN/A22.6520.7221.66
Price / Book0.894.214.363.58
Net Income-$78.26M-$23.99M$3.50B$393.99M
7 Day Performance-13.27%-7.62%-6.45%-7.09%
1 Month Performance-45.55%-11.41%-8.92%-10.32%
1 Year Performance-62.06%-6.70%-2.15%-8.04%

Avalo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVTX
Avalo Therapeutics
3.9302 of 5 stars
$6.72
-0.4%
$36.82
+447.9%
-61.6%$389.13M$60KN/A33
RARE
Ultragenyx Pharmaceutical
2.6423 of 5 stars
$16.14
-1.6%
$29.79
+84.6%
-46.0%$1.67B$673MN/A1,371
IMCR
Immunocore
2.2189 of 5 stars
$32.38
+2.0%
$53.00
+63.7%
-31.1%$1.63B$400.02MN/A524
NBTX
Nanobiotix
2.6059 of 5 stars
$32.87
+2.6%
$46.67
+42.0%
+26.1%$1.63B$36.87MN/A97
QURE
uniQure
3.1138 of 5 stars
$22.71
-0.4%
$56.83
+150.3%
-27.6%$1.60B$16.10MN/A221

Related Companies and Tools


This page (NASDAQ:AVTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners